Latest news with #AGENT
Medscape
11-08-2025
- Health
- Medscape
Paclitaxel Balloon Improves Complex Stent Care
TOPLINE: In patients with multilayer in-stent restenosis (ISR), treatment with a paclitaxel-coated balloon reduced target lesion failure (TLF) at 1 year to 23.8% compared with 40% with an uncoated balloon. The approach showed consistent benefits in patients with multilayer and single-layer ISR, with a greater absolute reduction in risk among multilayer cases. METHODOLOGY: A total of 600 patients with ISR were randomized in a 2:1 ratio to receive either a paclitaxel-coated or uncoated balloon treatment at 40 clinical sites in the US. Participants had ISR with a reference vessel diameter between 2 mm and 4 mm, and lesion length < 26 mm, with target stenosis > 50% for symptomatic or > 70% for asymptomatic cases before predilation. Randomization was stratified by multilayer vs single-layer ISR, and by the study's enrollment center, with 258 patients (44%) presenting with multilayer ISR. The primary endpoints was failure of the target lesion 1 year after treatment, an outcome which consisted of ischemia-driven target lesion revascularization, target vessel-related myocardial infarction, or cardiac death. TAKEAWAY: Among patients with multilayer ISR, failure of the target lesion was significantly less likely with a paclitaxel-coated balloon than with an uncoated device (23.8% vs 40%; hazard ratio, 0.55; 95% CI, 0.34-0.87; P = .01). Rates of revascularization of the target lesion were lower with a paclitaxel-coated balloon in cases of multilayer ISR (17.4% vs 37.8%; P = .0003), as were rates of target vessel-related myocardial infarction (5.9% vs 17.2%; P = .005). Patients with multilayer ISR experienced higher overall rates of TLF than those with single-layer ISR (29% vs 15.7%; P < .0001). Six cases of stent thrombosis occurred in the multilayer ISR group treated with uncoated balloons, with no cases reported in the group who received paclitaxel-coated balloons. IN PRACTICE: 'The treatment of multilayer ISR represents a unique clinical challenge for practicing clinicians. The incidence of recurrent ISR following PCI [percutaneous coronary intervention] is relatively high in this group of patients, and finding optimal solutions can be challenging because of the presence of multiple layers of existing stents,' the researchers wrote. 'Treatment with the paclitaxel-coated balloon led to greater absolute risk reduction in 1-year TLF among patients with multilayer ISR compared with an uncoated balloon,' they added. 'An important takeaway from this AGENT IDE subgroup analysis is the need for a lifetime management strategy in patients with ISR undergoing' PCI, Roxana Mehran, MD, of the Mount Sinai Fuster Heart Hospital, in New York City, and her colleagues, wrote in an editorial accompanying the journal article. The findings support the use of drug-coated balloons 'as a treatment option in high-risk patients with multilayer ISR, offering a chance to improve its otherwise poor prognosis. At the same time, the overall unfavorable outcomes observed in this condition highlight the importance of selecting the optimal strategy at the first ISR occurrence,' they added. SOURCE: This study was led by Ajay J. Kirtane, MD, SM, of Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation in New York City. It was published online on August 11, 2025, in Journal of the American College of Cardiology. LIMITATIONS: According to the authors, lesion preparation in this study was relatively conservative, with specialty balloons used in < 40% of cases. The researchers noted that more aggressive, mechanism-driven lesion preparation could have potentially further optimized outcomes, particularly in patients with complex multilayer disease. Additionally, intravascular lithotripsy and stent ablation, which are potential strategies for ISR, were not explored in the study. DISCLOSURES: Boston Scientific Corporation provided funding for the study. Kirtane received institutional funding to Columbia University and/or Cardiovascular Research Foundation from multiple organizations including Medtronic, Boston Scientific, Abbott Vascular, Amgen, CathWorks, Concept Medical, Philips, ReCor Medical, Neurotronic, Biotronik, Chiesi, Bolt Medical, Magenta Medical, SoniVie, and Shockwave Medical. He also holds equity options in Bolt Medical and Airiver. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
CNET
22-06-2025
- Entertainment
- CNET
Today's NYT Mini Crossword Answers for June 22
Looking for the most recent Mini Crossword answer? Click here for today's Mini Crossword hints, as well as our daily answers and hints for The New York Times Wordle, Strands, Connections and Connections: Sports Edition puzzles. Need some help with today's Mini Crossword? There are some tough clues today. Read on. And if you could use some hints and guidance for daily solving, check out our Mini Crossword tips. The Mini Crossword is just one of many games in the Times' games collection. If you're looking for today's Wordle, Connections, Connections: Sports Edition and Strands answers, you can visit CNET's NYT puzzle hints page. Read more: Tips and Tricks for Solving The New York Times Mini Crossword Let's get to those Mini Crossword clues and answers. The completed NYT Mini Crossword puzzle for June 22, 2025. NYT/Screenshot by CNET Mini across clues and answers 1A clue: Man's name with the same two vowels as BOAT, fittingly Answer: NOAH 5A clue: Watch in one sitting, as a TV series Answer: BINGE 6A clue: Mammal that cracks open sea urchins with rocks Answer: OTTER 7A clue: Publicist's concern Answer: BRAND 8A clue: Chooses, with "for" Answer: OPTS Mini down clues and answers 1D clue: Like some cold brew coffee Answer: NITRO 2D clue: How beer may be served Answer: ONTAP 3D clue: One helping to seal the deal Answer: AGENT 4D clue: Groups of buffalo Answer: HERDS 5D clue: ___ the Drag Queen, "RuPaul's Drag Race" winner who competed on "The Traitors" Answer: BOB
Forbes
15-04-2025
- Entertainment
- Forbes
Today's ‘Wordle' #1396 Hints, Clues And Answer For Tuesday, April 15th
How to solve today's Wordle. SOPA Images/LightRocket via Getty Images Looking for Monday's Wordle hints, clues and answer? You can find them here: We're very nearly at Wordle #1400, though that leaves us with just under 1,000 more five-letter words to go through before we run out. What then? I keep hoping Wordle will evolve into a 6-letter game, which would be just a tiny bit more challenging. In any case, let's solve today's! The Hint: Pale. The Clue: This Wordle begins with a vowel. Okay, spoilers below! . . . Today's Wordle Credit: Erik Kain Every day I check Wordle Bot to help analyze my guessing game. You can check your Wordles with Wordle Bot right here. BLADE was actually a pretty decent opening guess, leaving me with two yellow boxes and just 112 possible solutions. AGENT cut that down to four, and popped the yellow 'A' into green. I debated between AGENT, ANNEX and APNEA (one I didn't think of, despite living in an area filled with them, was ASPEN). I chose ASHEN and got lucky. Today's Bot Credit: Erik Kain Just like yesterday, I get 1 point for guessing in three and zero for tying the Bot, which is exactly what the Bot also gets. Our April totals are now: Erik: 6 points Wordle Bot: 10 points The word "ashen" comes from the Old English "æsce" meaning ash tree or ash (the residue of fire), combined with the adjectival suffix "-en", which means made of or resembling. So, "ashen" originally meant made of ash or resembling ash, especially in color—pale gray. FEATURED | Frase ByForbes™ Unscramble The Anagram To Reveal The Phrase Pinpoint By Linkedin Guess The Category Queens By Linkedin Crown Each Region Crossclimb By Linkedin Unlock A Trivia Ladder Let me know how you fared with your Wordle today on Twitter, Instagram or Facebook. Also be sure to subscribe to my YouTube channel and follow me here on this blog where I write about games, TV shows and movies when I'm not writing puzzle guides. Sign up for my newsletter for more reviews and commentary on entertainment and culture.
